Opiant Pharmaceuticals (OPNT) and Its Rivals Head-To-Head Comparison

Opiant Pharmaceuticals (NASDAQ: OPNT) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its peers? We will compare Opiant Pharmaceuticals to similar companies based on the strength of its earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Opiant Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Opiant Pharmaceuticals Competitors 190 909 1681 67 2.57

As a group, “Biopharmaceuticals” companies have a potential upside of 2.36%. Given Opiant Pharmaceuticals’ peers higher possible upside, analysts clearly believe Opiant Pharmaceuticals has less favorable growth aspects than its peers.


This table compares Opiant Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%
Opiant Pharmaceuticals Competitors -13,073.01% 230.26% -22.81%

Institutional & Insider Ownership

45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by company insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Opiant Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million $5.99 million 9.49
Opiant Pharmaceuticals Competitors $578.59 million $241.91 million -6.43

Opiant Pharmaceuticals’ peers have higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Opiant Pharmaceuticals has a beta of -0.75, indicating that its share price is 175% less volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals’ peers have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply